Published on 8/21/2021 in the Prospect News Structured Products Daily.
New Issue: Credit Suisse sells $8.78 million autocallable contingent income securities on pharma stocks
By Wendy Van Sickle
Columbus, Ohio, Aug. 23 – Credit Suisse AG, London Branch priced $8.78 million of autocallable contingent income securities due Aug. 16, 2024 linked to the least performing of the shares of Pfizer Inc., Amgen Inc. and Biogen Inc., according to a 424B2 filing with the Securities and Exchange Commission.
The notes will pay a contingent quarterly coupon at an annualized rate of 12% if each stock closes at or above its coupon barrier level, 60% of the initial level, on the relevant observation date.
The notes will be called at par plus the coupon if each stock closes at or above its initial share price on any quarterly call observation date after six months.
If the notes are not called and each stock finishes at or above its 60% barrier level, the payout at maturity will be par plus the final coupon. Otherwise, investors will lose 1% for each 1% decline of the least-performing stock from its initial level.
Credit Suisse Securities (USA) LLC is the agent with Morgan Stanley Smith Barney LLC as the dealer.
| Issuer: | Credit Suisse AG, London Branch
|
| Issue: | Autocallable contingent income securities
|
| Underlying stocks: | Pfizer Inc., Amgen Inc., Biogen Inc.
|
| Amount: | $8,775,000
|
| Maturity: | Aug. 16, 2024
|
| Coupon: | 12% annual rate, payable quarterly if each stock closes at or above coupon barrier level on the relevant observation date for that period
|
| Price: | Par of $10
|
| Payout at maturity: | If each stock finishes at or above barrier level, par plus the final coupon; otherwise, 1% loss for each 1% decline of the least-performing stock from initial level
|
| Call: | At par plus coupon if each stock closes at or above initial price on any quarterly call observation date after six months
|
| Initial levels: | $48.48 for Pfizer, $229.68 for Amgen, $342.25 for Biogen
|
| Coupon barrier levels: | $29.09 for Pfizer, $137.81 for Amgen, $205.35 for Biogen; 60% of initial prices
|
| Barrier levels: | $29.09 for Pfizer, $137.81 for Amgen, $205.35 for Biogen; 60% of initial prices
|
| Pricing date: | Aug. 13
|
| Settlement date: | Aug. 18
|
| Agent: | Credit Suisse Securities (USA) LLC
|
| Dealer: | Morgan Stanley Smith Barney LLC
|
| Fees: | 2.5%
|
| Cusip: | 22552Y697
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
